Yun Zhong
Stock Analyst at Wedbush
(2.06)
# 2,978
Out of 4,960 analysts
36
Total ratings
46.88%
Success rate
-7.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $7.54 | +430.50% | 3 | Aug 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $28 | $7.11 | +293.81% | 1 | Aug 11, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $212 → $220 | $194.30 | +13.23% | 2 | Aug 8, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Outperform | $9 → $8 | $3.43 | +133.24% | 2 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Reiterates: Outperform | $18 | $10.15 | +77.34% | 1 | Jun 23, 2025 | |
| KROS Keros Therapeutics | Reiterates: Neutral | $15 | $15.56 | -3.60% | 2 | May 30, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $8 | $1.55 | +416.13% | 1 | May 27, 2025 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Outperform | $32 | $3.64 | +779.12% | 2 | May 16, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $70 | $57.48 | +21.78% | 2 | Mar 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $55.89 | +30.61% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $7.00 | +71.43% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $9.53 | +193.81% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.00 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $7.61 | +110.25% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $160 | $20.22 | +691.30% | 11 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $15.70 | +192.99% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.70 | +488.24% | 1 | May 5, 2021 |
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $7.54
Upside: +430.50%
Sagimet Biosciences
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $7.11
Upside: +293.81%
Ascendis Pharma
Aug 8, 2025
Maintains: Outperform
Price Target: $212 → $220
Current: $194.30
Upside: +13.23%
Voyager Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $3.43
Upside: +133.24%
Wave Life Sciences
Jun 23, 2025
Reiterates: Outperform
Price Target: $18
Current: $10.15
Upside: +77.34%
Keros Therapeutics
May 30, 2025
Reiterates: Neutral
Price Target: $15
Current: $15.56
Upside: -3.60%
Camp4 Therapeutics
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $1.55
Upside: +416.13%
Rocket Pharmaceuticals
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.64
Upside: +779.12%
Protagonist Therapeutics
Mar 28, 2025
Reiterates: Outperform
Price Target: $70
Current: $57.48
Upside: +21.78%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $55.89
Upside: +30.61%
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $7.00
Upside: +71.43%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $9.53
Upside: +193.81%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.00
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $7.61
Upside: +110.25%
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $20.22
Upside: +691.30%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $15.70
Upside: +192.99%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $1.70
Upside: +488.24%